Use of Myostatin (Gdf-8) Antagonists for Improving Wound Healing and Preventing Fibrotic Disease
AssigneeOrico Limited
InventorsRavi Kambadur, Mridula Sharma, Alex Hennebry, Monica Senna Salerno de Moura
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of improving wound healing in a human or animal patient by inhibiting the activity of myostatin (GDF-8) using one or more myostatin antagonists. The present invention also relates to a method of treating fibrotic diseases or disorders comprising administering a myostatin antagonist.
Claims41
A method of improving tissue wound healing comprising the step of administering an effective amount of at least one myostatin antagonist to a human or non-human patient in need thereof.
A use of at least one myostatin antagonist in the manufacture of a medicament for improving tissue wound healing in a human or non-human patient in need thereof.
A pharmaceutical compound comprising at least one myostatin antagonist and a pharmaceutically acceptable carrier, when used in a method of improving wound healing in a human or non-human patient in need thereof.
At least one myostatin antagonist when used in a method of improving wound healing in a human or non-human patient in need thereof.
A method of treating fibrotic diseases or disorders comprising administering to a patient in need thereof a therapeutically effective amount of a myostatin antagonist.
Dependencies are inferred from the claim text.